Combination Chemotherapy in Treating Patients With Previously Untreated Rhabdomyosarcoma

Phase 3 Completed 702 enrolled Children's Oncology Group National Cancer Institute (NCI) · collab

RandomizedParallel-groupOpen-labelTreatment

Summary

This randomized phase III trial is comparing two different combination chemotherapy regimens to see how well each works in treating patients with previously untreated rhabdomyosarcoma or sarcoma. Drugs used in chemotherapy, such as dactinomycin, cyclophosphamide, vincristine, and topotecan, use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known which combination chemotherapy regimen is more effective in treating rhabdomyosarcoma.

Timeline

Start: 2002-09
Primary completion: 2007-10
Completion: —

Publications

de Traux de Wardin H, Dermawan JK, Vanoli F, Jiang SC, Singer S, Chi P, Tap W, Wexler LH, Antonescu CR. NF1-Driven Rhabdomyosarcoma Phenotypes: A Comparative Clinical and Molecular Study of NF1-Mutant Rhabdomyosarcoma and NF1-Associated Malignant Triton Tumor. JCO Precis Oncol. 2024 Apr;8:e2300597. doi: 10.1200/PO.23.00597.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Dactinomycin	Protein / enzyme biologic	—	Intravenous
Subject	Topotecan	Small molecule	—	Intravenous
Background	Cyclophosphamide	Other / unclassified	—	Intravenous
Background	Vincristine	Small molecule	—	Intravenous
Background	filgrastim	Protein / enzyme biologic	—	Subcutaneous
Background	sargramostim	Protein / enzyme biologic	—	Subcutaneous

Combination Chemotherapy in Treating Patients With Previously Untreated Rhabdomyosarcoma

Summary

Timeline

Publications

Drugs

Indications